<html>
<head>PUBMED IDs for ADIG</head>
<body bgcolor='#C5F0F2'><h1>ADIG</h1><a href='https://pubmed.ncbi.nlm.nih.gov/12414862/'>Association studies between microsatellite markers within the gene encoding human 11beta-hydroxysteroid dehydrogenase type 1 and body mass index, waist to hip ratio, and glucocorticoid metabolism.</a> November 5  2002<br><a href='https://pubmed.ncbi.nlm.nih.gov/20529912/'>Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM.</a> October 22  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21059681/'>The UCSC Cancer Genomics Browser: update 2011.</a> April 29  2010<br><a href='https://pubmed.ncbi.nlm.nih.gov/21908711/'>Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling.</a> April 13  2011<br><a href='https://pubmed.ncbi.nlm.nih.gov/22962493/'>PARADIGM-SHIFT predicts the function of mutations in multiple cancers using pathway impact analysis.</a> May 17  2012<br><a href='https://pubmed.ncbi.nlm.nih.gov/23813010/'>Learning subgroup-specific regulatory interactions and regulator independence with PARADIGM.</a> December 18  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/24297540/'>Drug Intervention Response Predictions with PARADIGM (DIRPP) identifies drug resistant cancer cell lines and pathway mechanisms of resistance.</a> August 15  2013<br><a href='https://pubmed.ncbi.nlm.nih.gov/27742786/'>Pheochromocytoma: The First Metabolic Endocrine Cancer.</a> October 16  2016<br><a href='https://pubmed.ncbi.nlm.nih.gov/28099931/'>A new semisynthetic cardenolide analog 3Î²-[2-(1-amantadine)- 1-on-ethylamine]-digitoxigenin (AMANTADIG) affects G2/M cell cycle arrest and miRNA expression profiles and enhances proapoptotic survivin-2B expression in renal cell carcinoma cell lines.</a> January 19  2017<br></body></html>
